222 related articles for article (PubMed ID: 18687142)
1. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.
Rhee SY; Liu TF; Kiuchi M; Zioni R; Gifford RJ; Holmes SP; Shafer RW
Retrovirology; 2008 Aug; 5():74. PubMed ID: 18687142
[TBL] [Abstract][Full Text] [Related]
2. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
3. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
4. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea.
Kim JY; Kim EJ; Choi JY; Kwon OK; Kim GJ; Choi SY; Kim SS
Clin Microbiol Infect; 2011 Aug; 17(8):1155-9. PubMed ID: 20946407
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
[TBL] [Abstract][Full Text] [Related]
8. Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.
Llácer Delicado T; Torrecilla E; Holguín Á
J Antimicrob Chemother; 2016 Feb; 71(2):362-6. PubMed ID: 26546669
[TBL] [Abstract][Full Text] [Related]
9. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
Low A; Prada N; Topper M; Vaida F; Castor D; Mohri H; Hazuda D; Muesing M; Markowitz M
Antimicrob Agents Chemother; 2009 Oct; 53(10):4275-82. PubMed ID: 19651917
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
11. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
Charpentier C; Descamps D
Viruses; 2018 Jan; 10(1):. PubMed ID: 29346270
[TBL] [Abstract][Full Text] [Related]
12. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.
Dimonte S; Babakir-Mina M; Aquaro S; Perno CF
Infection; 2013 Dec; 41(6):1097-102. PubMed ID: 23620062
[TBL] [Abstract][Full Text] [Related]
13. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
[TBL] [Abstract][Full Text] [Related]
14. HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.
Piralla A; Paolucci S; Gulminetti R; Comolli G; Baldanti F
Virol J; 2011 Mar; 8():149. PubMed ID: 21453487
[TBL] [Abstract][Full Text] [Related]
15. Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.
Acharya A; Tagny CT; Mbanya D; Fonsah JY; Nchindap E; Kenmogne L; Jihyun M; Njamnshi AK; Kanmogne GD
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106437
[No Abstract] [Full Text] [Related]
16. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
Karade S; Sen S; Sashindran VK
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
[TBL] [Abstract][Full Text] [Related]
17. Differences in the integrase and reverse transcriptase transmitted resistance patterns in Northern Poland.
Parczewski M; Leszczyszyn-Pynka M; Urbańska A
Infect Genet Evol; 2017 Apr; 49():122-129. PubMed ID: 28017912
[TBL] [Abstract][Full Text] [Related]
18. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
19. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.
Meixenberger K; Yousef KP; Smith MR; Somogyi S; Fiedler S; Bartmeyer B; Hamouda O; Bannert N; von Kleist M; Kücherer C
Virol J; 2017 Nov; 14(1):223. PubMed ID: 29137637
[TBL] [Abstract][Full Text] [Related]
20. Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors.
Oliveira MF; Ramalho DB; Abreu CM; Vubil A; Mabunda N; Ismael N; Francisco C; Jani IV; Tanuri A
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1788-92. PubMed ID: 22497664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
